AnHeart Therapeutics and Innovent Biologics Announce Exclusive License Agreement for Taletrectinib in Greater China – GlobeNewswire
HANGZHOU, China and SUZHOU, China and NEW YORK, May 31, 2021 (GLOBE NEWSWIRE) — AnHeart Therapeutics Co., Ltd. (AnHeart), a clinical stage oncology company focused on underserved patients in global markets, and Innovent Biologics, Inc. (HKEX: 01801) (Innovent), an innovative leading biopharmaceutical company today announced an exclusive license agreement for the co-development and commercialization of AnHearts lead drug candidate taletrectinib, a next-generation tyrosine kinase inhibitor (TKI)…
